Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.

Zeng, Jiping; Funk, Joel; Lee, Benjamin R; Hsu, Chiu-Hsieh; Messing, Edward M; Chipollini, Juan

Zeng, Jiping; Funk, Joel; Lee, Benjamin R; Hsu, Chiu-Hsieh; Messing, Edward M; Chipollini, Juan.

Afiliação

Zeng J; Department of Urology, The University of Arizona College of Medicine, Tucson, AZ, USA.
Funk J; Department of Urology, The University of Arizona College of Medicine, Tucson, AZ, USA.
Lee BR; Department of Urology, The University of Arizona College of Medicine, Tucson, AZ, USA.
Hsu CH; Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA.
Messing EM; Department of Urology, University of Rochester, Rochester, NY, USA.
Chipollini J; Department of Urology, The University of Arizona College of Medicine, Tucson, AZ, USA.

Transl Androl Urol ; 12(6): 960-966, 2023 Jun 30.

Article em En | MEDLINE | ID: mdl-37426602

Palavras-chave

Non-muscle invasive bladder cancer (NMIBC); gemcitabine; high-grade (HG); recurrence

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Transl Androl Urol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google